Matches in Wikidata for { <http://www.wikidata.org/entity/Q83805054> ?p ?o ?g. }
Showing items 1 to 31 of
31
with 100 items per page.
- Q83805054 description "clinical trial" @default.
- Q83805054 description "ensayu clínicu" @default.
- Q83805054 description "klinisch onderzoek" @default.
- Q83805054 description "клінічне випробування" @default.
- Q83805054 name "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 name "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 type Item @default.
- Q83805054 label "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 label "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 prefLabel "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 prefLabel "A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin." @default.
- Q83805054 P1132 Q83805054-5BDCAA61-89F3-4104-9653-08C94A5B050E @default.
- Q83805054 P1476 Q83805054-785B2849-7C51-44CA-B6F2-66563A6EF096 @default.
- Q83805054 P2899 Q83805054-AA7B5593-85D5-4A0A-B2D0-4F2465127EA1 @default.
- Q83805054 P3098 Q83805054-DB97A84D-6AF1-432C-95F5-B4A95DE082F5 @default.
- Q83805054 P31 Q83805054-55025089-8F0E-438F-A2D6-58357C86DA62 @default.
- Q83805054 P4135 Q83805054-3E216FE4-1483-4123-BD5E-904D9B48B785 @default.
- Q83805054 P580 Q83805054-EBA72EB5-96BE-4227-9D4D-194C34AC7A96 @default.
- Q83805054 P582 Q83805054-D8977EEE-DEC3-44A3-8990-0D45F08EC5A9 @default.
- Q83805054 P6099 Q83805054-1CD249B2-CFCD-40FD-850E-9466005C2D99 @default.
- Q83805054 P8363 Q83805054-7CB37C66-DCEF-4B77-9760-7DF6D4913632 @default.
- Q83805054 P1132 "+273" @default.
- Q83805054 P1476 "A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type 2 Diabetic Patients With Insufficient Glycemic Control." @default.
- Q83805054 P2899 "+18" @default.
- Q83805054 P3098 "NCT04233801" @default.
- Q83805054 P31 Q30612 @default.
- Q83805054 P4135 "+75" @default.
- Q83805054 P580 "2020-02-28T00:00:00Z" @default.
- Q83805054 P582 "2022-02-07T00:00:00Z" @default.
- Q83805054 P6099 Q42824827 @default.
- Q83805054 P8363 Q78089383 @default.